Press release Large-scale coronavirus vaccine manufacturing begins in Scotland
release Large-scale coronavirus vaccine manufacturing begins in Scotland Speciality vaccine
company Valneva has started commercial manufacturing of its promising COVID-19 vaccine candidate in
Livingston, West Lothian, Scotland.
Published 28 January 2021 From: Department for
Business, Energy & Industrial Strategy, Department of Health and Social Care, The Rt Hon Kwasi Kwarteng
MP, The Rt Hon Alister Jack MP, and The Rt Hon Matt Hancock MP
Valneva begins large-scale
vaccine manufacturing at its Livingston site in West Lothian up to 60 million jabs due to be
manufactured by the end of 2021 if the vaccine is approved UK government investment will support 100
new jobs at the site, a doubling of the workforce This follows a multi-million-pound joint
investment in the facility by the UK government last year as part of an agreement in principle to secure
early access to Valneva’s vaccine by the end of 2021. 60 million doses have already been secured for the
UK, with an option to acquire a further 130 million if the vaccine is proven to be safe, effective and
This investment will now support 100 new highly-skilled jobs for scientists and
technicians at the Livingston facility – doubling the workforce, putting Scotland at the forefront of the
UK’s fight against COVID-19, and boosting the UK’s resilience in dealing with current and future
pandemics by establishing a permanent vaccine manufacturing base.
vaccine candidate is currently in phase I/II trials and will still need to meet the necessary safety and
effectiveness standards and receive regulatory approval before it is rolled out at the end of the year.
However, if it is approved, manufacturing at risk now will mean that the UK can roll the vaccine out
across the country quicker.
Business Secretary Kwasi Kwarteng said:
Thanks to the
UK Vaccine Taskforce, we have ordered up to 60 million jabs of Valneva’s promising vaccine if it proves
to be safe, effective and suitable in its clinical trials this year.
manufacturing, we will have a running start at rolling these out as quickly as possible to protect the
British public if it receives regulatory approval.
This facility in Scotland, backed by
millions from the Government, will help us beat coronavirus and boost our resilience against future
The new facility establishes a permanent UK capability to manufacture inactivated
viral vaccines – one of the most proven, widely used types which is also used for flu, polio and rabies
If the vaccine proves successful and receives regulatory approval following a rigorous
assessment of available data, the Livingston facility will have the capacity to produce up to 250 million
doses annually for shipment across the UK and around the world.
Scottish Secretary, Alister
It’s incredibly exciting that a potential new COVID-19 vaccine will be manufactured
right here in Scotland, at the Valneva plant in Livingston.
This big step forward is a
testament to the talent and hard work of all the Valneva staff who have worked so far to get to this
The UK government has invested millions into developing the Valneva vaccine, which is
also supporting hundreds of highly skilled jobs in Scotland.
Chief Executive Officer of
Valneva Thomas Lingelbach said:
We are extremely pleased to have achieved these 2 important
milestones in such a short period of time. Our team in Scotland have done an amazing job to get
manufacturing started so quickly.
I would like to thank the UK Vaccines Taskforce and National
Institute for Health Research who have played vital roles in the rapid recruitment and enrolment of the
volunteers for the clinical study. We believe that our vaccine, assuming successful development, can make
a major contribution in the UK and beyond.
UK Health Secretary Matt Hancock said:
We’ve already secured 60 million doses of the Valneva vaccine which, if approved, will be another vital
tool in our fight against this virus.> The start of manufacturing in West Lothian today puts
Scottish expertise right at the heart of the UK vaccine programme.
Set to deliver millions
more jabs across all four nations, this is yet another fantastic example of the strength of our Union, as
we work together as one United Kingdom to tackle the virus.
Interim Chair of the UK
government’s Vaccines Taskforce Clive Dix said:
I am thrilled that manufacturing has begun in
Livingston as a result of the excellent work being done by Valneva in conjunction with the Vaccines
If approved this new vaccine will be a crucial part of our efforts to tackle
coronavirus – not just in the UK but around the world.
Through the Vaccines Taskforce, the UK
has secured early access to 367 million doses of seven of the most promising vaccines so far. To date,
the UK government has invested over £230 million into manufacturing a successful vaccine.
UK was the first country in the world to procure, authorise and then deploy both the Oxford/AstraZeneca
and Pfizer/BioNTech vaccines.
Production of the Oxford University/AstraZeneca vaccine started
last autumn where the bulk of the vaccine for the UK is being made in Oxfordshire and Staffordshire, with
filling into vials taking place in North Wales.
BORIS Johnson has been branded “grossly irresponsible" after visiting a Scottish laboratory despite
knowing there was a coronavirus outbreak at the site The Prime Minister, during his highly
criticised one-day trip north to “save the Union”, stopped in at bitotech firm Valneva’s vaccine
production facility in Livingston.
Also die Engländer sind nicht umsonst beim Impfen soweit vorne.
Sie haben auch bei Valneva schon bestellt, wo bleibt die EU Bestellung? Sie schauen, dass die
Impfstoffproduktion zum großen Teil (Valneva) im eigenen Land statt findet.
Alle Rechte vorbehalten. Nutzung ausschließlich für den privaten Eigenbedarf.
Eine Weiterverwendung und Reproduktion über den persönlichen Gebrauch hinaus ist nicht gestattet.
Kursdaten: Powered by Interactive Data Managed Solutions (IDMS). IDMS und die Datenlieferanten übernehmen keine Gewähr für die Richtigkeit, Vollständigkeit und Aktualität der Inhalte des Informationssystems. Die Kursdaten werden je nach Vereinbarung mit den Börsen/Handelsplätzen in Realtime, 15 Min. verzögert oder End-of-Day dargestellt. Weitere Hinweise entnehmen Sie bitte unseren AGB (§4 Abs.7).